Neurobehavioral Effects in HIV-Positive Individuals Receiving Highly Active Antiretroviral Therapy (HAART) in Gaborone, Botswana

Kathy Lawler3,4*, Kealeboga Jeremiah8, Mosepele Mosepele2,6, Sarah J. Ratcliffe3,5, Catherine Cherry8,9, Esther Seloilwe1, Andrew P. Steenhoff3,5,7

1 Center for the Study of HIV and AIDS, University of Botswana, Gaborone, Botswana, 2 Infectious Disease Care Center, Princess Marina Hospital, Gaborone, Botswana, 3 Center for AIDS Research and Botswana-U Penn Partnership, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, 4 Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, 5 Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, 6 Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, 7 Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America, 8 Monash University, Melbourne, Victoria, Australia, 9 Burnet Institute, Centre for Virology and Alfred Hospital, Department of Infectious Diseases, Melbourne, Victoria, Australia

Abstract

Objective: To explore the prevalence and features of HIV-associated neurocognitive disorders (HANDS) in Botswana, a sub-Saharan country at the center of the HIV epidemic.

Design and Methods: A cross sectional study of 60 HIV-positive individuals, all receiving highly active antiretroviral therapy (HAART), and 80 demographically matched HIV-seronegative control subjects. We administered a comprehensive neuropsychological test battery and structured psychiatric interview. The lowest 10th percentile of results achieved by control subjects was used to define the lower limit of normal performance on cognitive measures. Subjects who scored abnormal on three or more measures were classified as cognitively impaired. To determine the clinical significance of any cognitive impairment, we assessed medication adherence, employment, and independence in activities of daily living (ADL).

Results: HIV+ subjects were impaired for all cognitive-motor ability areas compared with matched, uninfected control subjects. Thirty seven percent of HIV+ patients met criteria for cognitive impairment.

Conclusion: These findings indicate that neurocognitive impairment is likely to be an important feature of HIV infection in resource-limited countries; underscoring the need to develop effective treatments for subjects with, or at risk of developing, cognitive impairment.

Introduction

Botswana has one of the highest human immunodeficiency virus (HIV) prevalence rates in the world, but it also has one of the most comprehensive nationally organized HIV testing and antiretroviral (ARV) therapy programs within sub-Saharan Africa [1]. Despite the initial success in Botswana in providing comprehensive free HIV testing and treatment with ARVs, there have been no studies to assess possible neurobehavioral complications in HIV-positive (HIV+) individuals on highly active antiretroviral treatment (HAART). In this paper we present the first systematic survey describing neurocognitive and affective functioning related to HIV infection in a HAART-treated Batswana cohort, where cde C is the predominant subtype.

It has been well documented that HIV enters the central nervous system (CNS) early after infection [2,3] and that as many as 30% of individuals with AIDS have neurocognitive impairment [4]. Even mild neuropsychological impairment has been associated with decreased vocational functioning, problems with medication management, driving, and activities of daily living [5,6]. Almost all of these data come from studies conducted in the United States [7,8] Europe [9], and the Pacific Region/Australia [10]. Less is known about the prevalence and characteristics of neurobehavioral complications of HIV infection in developing African countries such as Botswana, which carry the burden of the HIV epidemic [11–14]. Research has suggested that the incidence of HIV-associated neurocognitive disorder (HAND) may vary due to different viral clades. For example, in Uganda clades A and D are the predominant subtypes, and a study found 31% of HIV+ individuals had dementia, and 47% mild cognitive impairment [15]. An additional study in Uganda showed that risk factors for HAND were low CD4 cell count and advanced age [13]. In contrast, a study in Ethiopia, which is primarily cde C, did not find cognitive impairment on a screening measure of dementia in HIV+ subjects compared with control subjects [12]. Another study of cde C HIV+ subjects in several Pacific rim countries found cognitive
impairment (verbal fluency 33.6%), decreased fine motor speed (finger tapping 43%), and impaired gait (20%) [10]. Similarly, a study in southern India, with predominantly clade C HIV+ subjects, found mild to moderate cognitive impairment in 60.5% of subjects with no clinically identified functional impairment [16].

A study in China identified cognitive impairment in 34.2% of HIV+ subjects, with cognitive impairment in 39.7% of subjects who were co-infected with HIV and hepatitis C virus [17]. Most recently a study in South Africa, which is also predominantly clade C, found a prevalence of 42.4% mild cognitive disorder and 25.4% dementia in HIV+ patients beginning anti-retroviral therapy. Risk factors included lower levels of education, older age, and male gender [18].

While HAART has had a dramatic effect on the incidence and severity of HAND, its milder form continues to be prevalent. This may be due to a number of factors that include: delayed initiation of HAART, poor CNS penetration of many ARVs, drug resistance, potential ARV neurotoxicity, poor medication adherence, side-effects of long-term use of HAART, such as cardiovascular disease, and chronic HIV brain infection [19,20].

Diagnosis of HAND is of great importance, not only clinically, but also to ensure appropriate allocation of scarce medical resources in the regions worst affected by the HIV epidemic. To address this, the aims of the present study were twofold: 1) To determine the prevalence of cognitive impairment in an HIV-positive population in Botswana, a country with one of the highest HIV rates in the world, and 2) To assess, from a neurocognitive perspective, the effectiveness of HAART regimens with differing CNS penetration scores for HIV-positive patients in a resource-limited setting.

Methods

Ethics Statement

This research study was approved by the Institutional Review Boards (IRBs) from the Botswana Ministry of Health, Princess Marina Hospital (PMH), University of Pennsylvania, and Monash University. Written informed consent was obtained from the participants after the study had been fully explained to them.

HIV+ Participants: Sixty HIV+ subjects were asked to participate. They were approached from March through August 2009 during routine follow-up visits at the Infectious Disease Care Clinic (IDCC) at PMH in Gaborone, Botswana. A small reimbursement ($4.00) for participation was offered. Inclusion criteria were men and women with: (1) documented HIV-positive status; (2) ages 21–50; (3) ambulatory status; and (4) the ability to comprehend study procedures and provide informed consent. All patients were prescribed HAART. Exclusion criteria eliminated patients beginning anti-retroviral therapy. Risk factors included lower levels of education, older age, and male gender [18].

While HAART has had a dramatic effect on the incidence and severity of HAND, its milder form continues to be prevalent. This may be due to a number of factors that include: delayed initiation of HAART, poor CNS penetration of many ARVs, drug resistance, potential ARV neurotoxicity, poor medication adherence, side-effects of long-term use of HAART, such as cardiovascular disease, and chronic HIV brain infection [19,20].

Diagnosis of HAND is of great importance, not only clinically, but also to ensure appropriate allocation of scarce medical resources in the regions worst affected by the HIV epidemic. To address this, the aims of the present study were twofold: 1) To determine the prevalence of cognitive impairment in an HIV-positive population in Botswana, a country with one of the highest HIV rates in the world, and 2) To assess, from a neurocognitive perspective, the effectiveness of HAART regimens with differing CNS penetration scores for HIV-positive patients in a resource-limited setting.

Control Subjects

Eighty demographically matched HIV-negative (HIV-) individuals who met the inclusion/exclusion criteria, also agreed to participate. All controls received a negative ELISA HIV test on the day of neurobehavioral testing, and were recruited from Tebelelope Voluntary Counseling and Testing Centre (TVCTC), a free government sponsored HIV testing centre adjacent to PMH.

Procedure

Subjects underwent a standardized neuropsychological examination, a structured psychiatric interview of depression/anxiety, and an assessment of activities of daily living (ADL). Assessments were in the preferred language (Setswana or English) for each subject, administered by a Motswana medical student fluent in both languages (KJ) or a neuropsychologist from the University of Pennsylvania (KLL). Testing procedures were standardized for these two examiners. The neuropsychologist thoroughly trained and closely supervised the medical student. All consent forms, questionnaires, and tests were translated into Setswana and back translated. For patients with limited reading ability, the ADL scale was administered orally by the examiners. The investigators evaluated neuropathy using a targeted history composed of structured validated questions designed to elicit symptoms of distal sensory loss or pain. Structured interviews and chart reviews were performed to obtain information about medical and psychiatric history, pattern of substance use, adherence to ARV medication, marital status, education, employment, current medications, current and nadir CD4 lymphocyte counts, and viral loads. The assay used for viral load testing in Botswana is the Amplicor HIV-1 Monitor Assay, Roche Molecular Systems, Branchburg, New Jersey. The lower limit of detection of the assay is 400 copies/mL. Viral loads were categorized dichotomously as detectable (>400 copies/mL) versus undetectable (<400 copies/mL).

Measures

The neuropsychological test battery assessed six cognitive-motor ability areas: processing speed, psychomotor speed, verbal learning/memory, executive function, language, and fine motor speed. Research has shown that these ability areas are consistently affected by HAND in developed countries [21–23] and more recently in several resource-limited countries [14,16,17,24–26]. This battery was primarily made up of tests that have been widely used to study HIV infection in the United States, Europe, and multi-national studies: in developing regions [19,23]. In addition, we included a modified auditory verbal learning test, The Botswana Auditory Verbal Learning Test (BAVLT). This test was designed for administration in either Setswana or English, and is more appropriate for use in Botswana than existing verbal learning tests [27].

Participants underwent structured psychiatric interviews to assess major depressive disorder (MDD), generalized anxiety disorder (GAD), and alcohol use. To explore the clinical significance of neuropsychological impairment, we assessed independence in activities of daily living (ADL), employment status, and adherence to ARV regimens.

Digit Symbol Coding (DSC) sub-test of the WAIS-III [28]

The DSC is a paper-pencil measure of processing speed. Subjects use a key of digit-symbol pairs at the top of the test page and are required to fill in the correct symbol for each number as quickly as possible within a 120 second time limit. The score is the number of correct symbols transcribed within the time limit.

Verbal Fluency for Action

Action fluency (AF) is a test of language that taps into frontal neural systems [29] and has been shown to be sensitive to the neurocognitive effects of HIV infection in subjects in both developed and resource-limited countries [30]. This task requires subjects to generate as many action words (verbs) as they can within a time limit. The score is the total number of correct words produced within one minute.
Botswana Auditory Verbal Learning Test (BAVLT)

The BAVLT [27] is similar to other verbal learning tests, including the WHO/UCLA Auditory Verbal Learning Test, which has been shown to be sensitive to HIV in several developing countries [16,22,31]. The BAVLT is a list-learning task, composed of 16 words from 4 categories, and an interference word list (16 different words, 4 different categories). This test has both immediate and thirty-minute delay free recall trials, and a recognition trial. Words were carefully selected so that they would be familiar to all Batswana, even subjects with minimal or no education, and translated easily between Setswana and English. Scores analyzed included the total number of words learned for the 5 trials (TL), immediate free recall (IR), delayed free recall (DR), and recognition (R).

Trail Making Test A (TA) [32]

The Trail Making Test A (TA) assesses psychomotor speed, attention, sequencing, and visual scanning efficiency. This task required participants to connect numbered circles, randomly scattered over a sheet of paper, sequentially from 1 to 25. The score is the time taken to correctly connect the numbered circles.

Color Trails 2 (CT2) [33]

In addition to the skills required for Trail Making Test A, this test also assesses set-shifting ability. To minimize cultural bias, no letters or written instructions are used. It consists of numbered colored circles from 1 to 25, in bright yellow and pink. Each number is represented twice, once in each color. Using a pencil the subject is required to connect the numbers sequentially, while alternating between the two colors. The score is the time taken to correctly connect the numbered circles.

Grooved Peg Board Test (GPT)

This test measures fine motor speed and manual dexterity for each hand. Subjects were required to insert small grooved pegs into matched holes on a board. Each hand is tested separately and the score is the time taken to correctly place all of the pegs [34].

Primary Care Evaluation of Mental Disorders (Prime-MD) [35]

Three modules were administered from the Prime-MD. Mood Module (MM): The MM is a focused interview, that follows DSM-IV criteria [36], for screening medical patients for current depression, composed of simple “yes” and “no” questions. If five or more of the nine symptoms are present and one of these symptoms is sadness/hopeless or anhedonia, then a diagnosis of MDD is supported. The MM has been successfully used to diagnose depression in patients with HIV and was found to have a sensitivity of 77% and specificity of 84% [37]. In addition, it was previously validated in HIV+ Batswana individuals [38].

Generalized Anxiety Module (GAM): The Generalized Anxiety Module consists of 7 simple “yes” and “no” questions aimed at diagnosing Generalized Anxiety Disorder. Subjects must acknowledge feeling anxious and have three or more symptoms of anxiety to meet DSM-IV criteria for a Generalized Anxiety Disorder.

Alcohol Module (AM): This inventory is composed of six “yes” and “no” questions about alcohol use during the past six months, aimed at gauging how much alcohol has interfered with activities such as relationships, school/work, and driving. The higher the score, the more alcohol has interfered with daily responsibilities.

Activities of Daily Living Scale (ADL)

This questionnaire was selected for its wide use and demonstrated validity in studies of medically ill and dementia popula-

tions, including HIV subjects in developing countries [39]. It is a 14-item scale measuring physical self-maintenance (e.g., dressing, bathing) and instrumental activities of daily living (e.g., preparing meals, taking medications). Each item is rated on a four-point scale: (1) no difficulty at all; (2) has some difficulty; (3) needs some assistance; (4) can’t do at all. Higher scores indicate more impairment in daily functioning.

Data Analysis. We performed descriptive analyses and comparisons to examine the demographic and clinical characteristics of patients. All analyses were conducted using StataMP 10.0 (College Station, TX). Correlation coefficients were used to assess relationships between continuous variables. Student’s t-test and analysis of variance (ANOVA) were used for comparisons of normally distributed variables. Kruskal-Wallis rank was used for non-normal variables, and Fisher’s exact tests and Chi2 tests were used for categorical variables. Variables were transformed to normality, as possible. The relative differences in cognitive impairment between the HIV+ and HIV- groups, adjusted for demographic (age, gender, education, and opportunistic infection) and HIV characteristics (nadir/current CD4 count, time since beginning HAART, a detectable viral load), was assessed using regression models. As this was an exploratory study, alpha was set at 0.05 to determine statistical significance. Additionally, the study was designed to detect differences between HIV+ and HIV- subjects in continuous cognitive impairment measures of at least 0.5 standard deviation units.

Results

The two groups were comparable in age, education, and gender distribution (Table 1). HIV+ patients were more likely to be married whereas HIV- controls were more likely to have chosen to do the study test in Setswana. All of the HIV+ patients were prescribed HAART, having met criteria for HAART initiation as defined in the Botswana National HIV Guidelines [40], and none of the HIV- participants were prescribed HAART.

Laboratory Characteristics

These are summarized in Table 2. Nadir CD4 counts were unavailable for eight HIV+ subjects, so analyses between laboratory values and neuropsychological measures excluded them. Nadir CD4 count was not associated with cognitive impairment (p=0.3), nor was current CD4 count (p=0.3). Furthermore, nadir CD4 count was not associated with depression (p=0.5), anxiety (p=0.3), or difficulty with ADL (p=0.14). Similarly, current CD4 count was not associated with any of these measures (depression p>0.99, anxiety p=0.2, ADL p=0.12).

Ninety-three percent of subjects in our sample had an undetectable viral load (i.e. viral load was <400 copies/mL). Thus, it was not feasible to analyze the data as a continuous outcome. Viral load was therefore examined as a dichotomous outcome (detectable versus undetectable). We found no association between viral load and any of depression, anxiety, or ability to perform ADL, even at a bivariate level.

Neuropsychological Performance for HIV+ and HIV- Subjects

Table 3 summarizes raw scores (means and standard deviations) on the neuropsychological tests, and also indicates effect sizes comparing the HIV+ group to the uninfected group, adjusted for the effects of age, education, gender, and history of opportunistic infection. Mean t-scores for the neuropsychological tests all showed significant group effects. The HIV+ group was significantly impaired compared to the HIV- group on measures of processing speed (DSC, p<0.01), verbal learning and free recall.
memory (BAVLT: TI p = 0.01, IR p < 0.01, DR p < 0.01), but not recognition (R p = 0.64). HIV+ subjects made more errors on the BAVLT, which included false positive (p < 0.01) and intrusion errors (p = 0.01).

The HIV+ group was also impaired when assessing fine motor speed/dexterity in both dominant (D/GPB, p = 0.04) and non-dominant hands (ND/GPB, p = 0.01), psychomotor speed (TA, p = 0.01), executive functioning (CT2, p < 0.01), and language (AF, p < 0.01).

### Table 1. Demographic Characteristics of Subjects.

| DEMOGRAPHIC CHARACTERISTICS | HIV- CONTROL SUBJECTS (N = 80) | HIV+ SUBJECTS (N = 60) | P-VALUE |
|-----------------------------|-------------------------------|-----------------------|---------|
| Age in years (SD)           | 35.8 (6.7)                    | 37.5 (6.2)             | 0.11    |
| Total education in years (SD)| 9.3 (4.2)                     | 8.6 (4.2)              | 0.24    |
| No education                | 10%                           | 13.3%                 |         |
| Primary                     | 18.8%                         | 20%                   |         |
| Secondary                   | 58.8%                         | 51.7%                 |         |
| Post-Secondary              | 12.5%                         | 15%                   |         |
| Gender (% male)             | 50%                           | 48.3%                 | 0.87    |
| Marital status:             |                               |                       |         |
| Single                      | 79.7%                         | 58.3%                 | 0.01    |
| Married                     | 20.3%                         | 41.7%                 |         |
| Employment status:          |                               |                       |         |
| Employed                    | 77.5%                         | 71.7%                 | 0.44    |
| Unemployed                  | 22.5%                         | 28.3%                 | 0.13    |
| Months worked in last year  | 8.7 (4.9)                     | 7.6 (5.2)             |         |
| Language of test administration: |                        |                       |         |
| Setswana                    | 78.8%                         | 61.7%                 | 0.03    |
| English                     | 17.5%                         | 36.7%                 |         |
| Both                        | 3.8%                          | 1.7%                  |         |

doi:10.1371/journal.pone.0017233.t001

### Table 2. Clinical and Laboratory Characteristics of 60 HIV Infected Subjects (Mean scores and standard deviations in parentheses).

| LABORATORY CHARACTERISTICS | PERCENT | MEAN | STANDARD DEVIATION | RANGE |
|----------------------------|---------|------|--------------------|-------|
| Current CD4 count          | 416.4%  | 198.5| 82.0–955.0         |       |
| Subjects with current CD4<200 | 15%      |       |                    |       |
| Nadir CD4                  | 97.6%   | 49.9 | 4.0–168.0          |       |
| Time since HIV diagnosis (years) | 4.6 | 2.5 | 0.5–15.1 | |
| Viral Load: <400           | 93.3%   | 93.3%| 6.7%               |       |
| On HAART (>3 drugs)        | 100%    |      |                    |       |
| HAART treatment duration (years) | 4.1 | 2.1 | 0.1–10.8 | |
| Self-reported adherence as “always” | 78.3% |   |                   | |
| Peripheral opportunistic infections: | 40% | | | |
| Prior opportunistic infections: |       | |           |
| TB                         | 35%     |      |                    |       |
| Syphilis                   | 22%     |      |                    |       |

doi:10.1371/journal.pone.0017233.t002

### Table 3. Performance on Neuropsychological Measures.

| NEUROPSYCHOLICAL MEASURES | CONTROLS (N = 80) | HIV+ (N = 60) | P-VALUE |
|----------------------------|-------------------|---------------|---------|
| Processing Speed:          |                   |               | <0.01   |
| Symbol Digit Coding (SDC)  |                   |               |         |
| Verbal Learning/Memory (BAVLT): |            |               |         |
| Total Words (T)            | 54.3 (12.02)      | 48.4 (14.84)  | 0.01    |
| Immediate Recall (IR)      | 12.1 (2.2)        | 9.8 (2.3)     | <0.01   |
| Delayed Recall (DR)        | 12.4 (2.3)        | 10.2 (2.8)    | <0.01   |
| Recognition (R)            | 15.3 (0.9)        | 14.8 (2.2)    | 0.64    |
| Intrusion Errors (Total)   | 2.7 (4.2)         | 4.4 (5.3)     | 0.01    |
| False Positive Recognition Errors | 1.5 (2.8) | 2.8 (3.5) | <0.01 |
| Fine Motor Speed/Dexterity (GPB): |          |               |         |
| Dominant Hand Time (seconds) | 80.2 (21.7) | 86.4 (25.1) | 0.04    |
| Non-dominant Hand Time (seconds) | 88.0 (16.8) | 102.5 (38.1) | 0.01    |
| Executive Functions:       |                   |               |         |
| Color Trails 2 (CT2, Time in seconds) | 123.7 (60.10) | 164.9 (98.4) | <0.01   |
| Color Trails 2 (Errors)    | 0.4 (0.9)         | 0.9 (1.5)     | 0.03    |
| Language:                  |                   |               | <0.01   |
| Action Fluency (AF, Total Words) | 11.6 (3.8) | 9.3 (3.9) |         |
| Psychomotor Speed:         |                   |               |         |
| Trail Making Test A (TA, seconds) | 52.6 (23.9) | 68.7 (38.5) | 0.01    |

### Psychological Measures

| PRIME-MD                  | CONTROLS (N = 80) | HIV+ (N = 60) | P-VALUE |
|---------------------------|-------------------|---------------|---------|
| Major Depressive Disorder | 28.8%             | 35%           | 0.47    |
| Suicidal Ideation         | 7.5%              | 15%           | 0.18    |
| Generalized Anxiety Disorder | 25%               | 41.7%         | 0.04    |

Raw scores, means, standard deviations (in parentheses), and effect sizes on individual neuropsychological test measures for HIV+ and HIV- subjects.

doi:10.1371/journal.pone.0017233.t003

Association Between Neuropsychological Impairment, Alcohol Use and Psychological Measures (Anxiety/Depression)

There was no difference between the two groups with respect to alcohol use (p = 0.6). Subjects in both groups reported very minimal use of alcohol and virtually no participants reported current substance abuse.

Forty-two percent of HIV+ subjects met criteria for Generalized Anxiety Disorder (GAD), which was higher than the 25% in controls (p = 0.04). In contrast, incidence of Major Depressive Disorder (MDD) was similar for the two groups (HIV+ 35%, HIV+ 7.5%, p = 0.18). There was no difference in neuropsychological performance for depressed (n = 96) and non-depressed subjects (n = 44). These findings will be described in detail elsewhere.

Definition of Cognitive Impairment and Association with other Factors

According to recently updated research definitions of HAND, Asymptomatic Neurocognitive Impairment (ANI) is defined by performance at least 1 SD below the mean of demographically adjusted normative scores in at least two cognitive areas, with at least 5 cognitive domains measured. Criteria for ANI also require that the impairment: does not occur solely as part of delirium, cannot be explained by other co-morbidities, pre-existing conditions, depression, or substance abuse, and does not interfere with everyday functioning [4]. To be consistent with this definition while account for some non-normality in results achieved by control subjects on grooved peg board testing, the lowest 10th
percentile of results achieved by HIV- control subjects was defined as the lower limit of normal performance for the six cognitive-motor measures studied here. Lower performance than this on at least 3 tests (and thus at least two cognitive areas) was defined as impaired to at least the level of ANI. A substantial number of HIV+ subjects tested as cognitively impaired using this definition. Thirty seven percent of HIV+ subjects scored impaired on three or more measures and were defined as cognitively impaired (Table 4). Univariate analysis revealed that cognitive impairment was associated with increasing age, fewer years of education and having been married. Cognitive impairment was not associated with number of years since HIV diagnosis, CD4 count (current or nadir), neuropathy, depression, medication adherence, or alcohol use (Table 5). Multivariate analysis demonstrated, among HIV+ patients, fewer years of education (p = 0.007) and older age (p = 0.002) were independently associated with cognitive impairment (See Table 6).

### HAART Regimen and Cognitive Function Among HIV+ Subjects

All HIV+ subjects were on HAART and drug regimens were recorded for 95% of subjects. Seventy-eight percent of patients were on standard first line regimens consisting of two nucleoside (or nucleotide) analog reverse transcriptase inhibitors (one of Zidovudine, Tenofovir or, Stavudine, together with either Lamivudine or Emtricitabine), and either a non-nucleoside analog reverse transcriptase inhibitor (Nevirapine or Efavirenz), or a protease inhibitor (ritonavir-boosted Lopinavir). In addition, two patients were using Abacavir as a fourth drug. Seventeen percent of patients were using second line therapy, which in all cases consisted of zidovudine, lamivudine and lopinavir/ritonavir. Each drug was given a CNS penetration score [41] to determine whether the total CNS penetration score of the regimens was associated with cognitive impairment. Antiviral drugs with high ability to penetrate the blood-brain barrier were given a penetration score of 1 (nevirapine, lopinavir/ritonavir, abacavir, zidovudine), drugs with intermediate ability were given a score of 0.5 ( stavudine, lamivudine, emtricitabine, efavirenz), and poor ability was scored 0 (tenofovir). The mean penetration score of HAART regimens used by patients was 2 (range 0.5–3.5). There was no difference (p = 0.6) in CNS penetration scores for patients who were cognitively impaired and patients who were not cognitively impaired (Table 5)

### Activities of Daily Living, Adherence, and Employment

Slightly over 21% of HIV+ subjects reported difficulty adhering to ARV regimens, which they attributed exclusively to memory difficulties. Subjects who reported problems with adherence did not differ on any of the demographic variables of age (p = 0.2), education (p = 0.5), gender (p = 0.2), or marital status (p>0.99). Despite subjective complaints of difficulty remembering to take medication, these subjects were not more impaired on objective memory measures on the BAVLT than patients reporting high levels of medication adherence (TL p = 0.8, IR p = 0.4 DR p = 0.7). Details of the ADL results are described in detail elsewhere.

### Discussion

There are two main findings in this study. First, HIV+ subjects were impaired on neuropsychological measures when compared to normal control subjects. Second, cognitive impairment was associated with increasing age, fewer years of education and having been married. Cognitive impairment was not associated with number of years since HIV diagnosis, CD4 count (current or nadir), neuropathy, depression, medication adherence, or alcohol use. Multivariate analysis demonstrated, among HIV+ patients, fewer years of education (p = 0.007) and older age (p = 0.002) were independently associated with cognitive impairment.

---

### Table 4. HIV+ Subjects Impaired on Neuropsychological Measures.

| NEUROPSYCHOLOGICAL MEASURE | CUT OFF | IMPAIRED* |
|-----------------------------|---------|-----------|
| Processing Speed: Digit Symbol Coding | 32 | 32% |
| Memory: Delayed Recall (BAVLT) | 9 | 37% |
| Language/Verbal Fluency: Action Fluency | 7 | 38% |
| Psychomotor Speed: Trails A | 78.5 | 30% |
| Executive Function: Color Trails 2 | 221.2 | 20% |
| Fine Motor Speed: GPB Dominant Hand | 100 | 22% |
| Fine Motor Speed: GPB Non-dominant Hand | 108.5 | 25% |
| Cognitive Impairment | >3 impaired scores | 37% |

*The lower 10th percentile of results achieved by HIV- control subjects was defined as the lower limit of normal performance for 6 cognitive tests and 2 measures of fine motor speed. Lower performance than this was defined as impaired. HIV+ subjects who scored impaired on three or more tests were defined as cognitively impaired. The cut off results used to differentiate normal and impaired performance are shown here.

doi:10.1371/journal.pone.0017233.t004

---

### Table 5. Characteristics of Impaired and Non-Impaired HIV+ Subjects.

| HIV+ PATIENT FACTORS | IMPAIRED (N = 22) | NON-IMPAIRED (N = 38) | P VALUE |
|-----------------------|------------------|------------------------|---------|
| Age                   | 42 (6.1)         | 34.8 (4.5)             | <0.0001 |
| Education (years)     | 5.8 (4.1)        | 10.3 (3.4)             | <0.0001 |
| Employment (Full-Time)| 16 (73%)         | 19 (50%)               | 0.1     |
| Never Married         | 15 (68%)         | 34 (89%)               | 0.04    |
| Neuropathy            | 8 (36%)          | 16 (42%)               | 0.7     |
| Alcohol Use           | 4 (18%)          | 8 (21%)                | 0.8     |
| Years Since HIV Diagnosis | 4.6 (1.6)  | 4.6 (2.9)             | 0.9     |
| Nadir CD4 (range in parentheses) | 109 | 137 (4–45) | 0.1 |
| Current CD4           | 373 (175–713)   | 442 (82–955)           | 0.3     |
| Detectable Virus      | 2 (9%)           | 2 (5%)                 | 0.6     |
| Years on HAART        | 4.4 (1.7)        | 3.9 (2.3)              | 0.3     |
| Depression            | 7 (32%)          | 14 (37%)               | 0.7     |
| Non-Adherence         | 3 (14%)          | 10 (27%)               | 0.3     |
| CPE Score             | 1.95 (0.49)      | 2.01 (0.62)            | 0.6     |

Univariate analysis of associations between patient factors and cognitive impairment for HIV+ subjects, defined as impaired and non-impaired. Mean scores/years and standard deviations (in parentheses).
doi:10.1371/journal.pone.0017233.t005

---

### Table 6. Logistic regression model of factors independently associated with cognitive impairment in this cohort.

| Variable | Odds ratio | 95% Confidence interval | p value |
|----------|------------|-------------------------|---------|
| Age in years | 1.28 | 1.1, 1.49 | 0.002 |
| Years of education | 0.76 | 0.62, 0.93 | 0.007 |

(Model R² = 0.40, p<0.0001).
doi:10.1371/journal.pone.0017233.t006
demographically matched controls for all cognitive-motor ability areas, which included processing speed, verbal learning/memory, language, psychomotor speed, executive function, and fine motor speed (dominant and non-dominant hands). Using a definition of impairment as scoring below the 10th percentile of results achieved by control subjects on three or more measures of cognition and/or fine motor speed, a significant proportion (37%) of HIV+ subjects were cognitively impaired. Second, there was no difference in CNS penetration scores for impaired and non-impaired HIV+ subjects, but those who were cognitively impaired were older and had less education than subjects who were not cognitively impaired.

This study has several limitations, which include a relatively small sample size, the use of a symptom scale to identify peripheral neuropathy rather than a neuromedical assessment, and an ADL scale that may not have been sensitive to detect subtle changes in activity levels in this Batswana cohort.

The prevalence of cognitive impairment (37%) is similar to prior research, which used the International HIV Dementia Scale (IHDS) and found 38% of HIV+ Batswana subjects, 97.5% of whom were on HAART, to be cognitively impaired [27]. We had anticipated that cognitive impairment would be associated with regimens with lower CNS penetration scores since prior studies have demonstrated that regimens with higher CNS penetration scores are associated with better control of CNS viral load [41] and better cognitive outcomes [42]. But there was no difference in CNS penetration scores between HIV+ impaired and unimpaired subjects.

All of the HIV+ subjects were prescribed HAART, which was expected to suppress HIV viral loads and improve current CD4 counts. Most patients had undetectable plasma HIV viral loads. Thus we hypothesized that neuropsychological status would be related to nadir CD4, but not current CD4. The results did not confirm this, and neither lower nadir nor current CD4 T-cell counts were a risk factor for cognitive impairment. It is possible that CD4 count (nadir and current) was not associated with cognitive impairment because most subjects in this study had achieved normal or near-normal CD4 counts. Most patients had undetectable plasma HIV viral loads. Therefore, we hypothesized that neuropsychological status would be related to nadir CD4, but not current CD4. The results did not confirm this, and neither lower nadir nor current CD4 T-cell counts were a risk factor for cognitive impairment. It is possible that CD4 count (nadir and current) was not associated with cognitive impairment because most subjects in this study had achieved normal or near-normal CD4 counts, and subjects with a known history of CNS opportunistic infections were excluded.

In the current study, older age and fewer years of education within HIV+ subjects were associated with cognitive impairment. A recent study of HAND in South Africa also found a significant association with lower levels of education and older age [18]. Future large scale studies of healthy Batswana with diverse ages and educational backgrounds will be needed to develop norms that can be used to confidently classify HIV-related impairments in individual cases.

Verbal learning and free recall memory were impaired for HIV+ subjects, but recognition memory was not. This is consistent with prior studies showing impaired free recall due to a retrieval deficit, but intact recognition memory [43]. Qualitatively, HIV+ subjects demonstrated executive dysfunction on the BAVLT, as illustrated by more intrusion and false positive errors, which is reflective of the frontal-striatal brain damage that is typical of HIV. This pattern of impairment is in agreement with previous studies in sub-Saharan Africa [13,14,44].

From prior work in the same setting, we anticipated a relatively high prevalence of depression in HIV+ individuals [38]. However, we were surprised by the similarly high level of depression and suicidal ideation in the demographically matched, uninfected control group. The double rate of suicidality in HIV+ subjects is clinical meaningful, but the study lacked the power to find it statistically significant. These data suggest that depression is common in both HIV+ and HIV- adults in this setting and that HIV infection itself may not be the explanation (or the only explanation) for the high rate of depression previously described in HIV+ adults in Botswana. It has been suggested that rapid changes in Batswana society have contributed to the high rate of depression and suicide [45]. This includes changes in gender roles as women have gained access to education, a decrease in marriage, and employment patterns that have led to a steady migration away from the traditional patriarchal family structure to a more isolated lifestyle in urban settings.

HIV+ subjects did not report difficulty with routine daily activities on the ADL scale, and were as likely to be employed as the HIV- control subjects. One possible explanation for this is that the neuropsychological deficits do not have the same relevance to everyday activities for HIV+ individuals in Botswana, as compared to US studies where even mild cognitive impairment has been shown to adversely impact vocational activities [6]. An alternative explanation is that the ADL scale used in this study may not be valid in developing countries, such as Botswana, where people have very different educational, cultural, and linguistic backgrounds from those in the United States, Europe, and Australia. Other researchers have pointed out that until more culturally appropriate ADL measures have been validated for a particular population, it may be more reliable to focus on objective neuropsychological test performance, especially for comparison across international settings [23]. HIV-related changes in cognitive ability may be much less likely to cause obvious functional decline in cultures that have fewer demands on such cognitive abilities [4].

Thus the addition of an asymptomatic category of neurocognitive impairment, such as ANI, may be particularly important in these types of settings to prevent such cases of cognitive impairment from being missed. The recognition of mild cognitive impairment in asymptomatic individuals may encourage more frequent neuropsychologic follow-up for individuals of ANI, help with decisions related to the initiation of ARVs independent of biomarkers, and guide the selection of ARV regimens.

In conclusion, neuropsychological impairment in this Batswana sample was associated with HIV infection, and the pattern was similar to neuropsychological studies previously carried out in developed and developing countries, including sub-Saharan Africa. Within the HIV+ group, those who met criteria for cognitive impairment were older and had less education than patients who were not cognitively impaired. These findings indicate that HAND is likely to be important among HAART-treated HIV individuals in developing countries.

Acknowledgments

The authors would like to thank the Ministry of Health of the Republic of Botswana for permission to carry out this project. We thank Dr Rameshwar Thakur for help with the Setswana translations and IRB applications, Rosemarie Kappes for assistance with IRB applications, Dr. Robert Heaton for providing the modified ADL Scale, Dr. Doreen Ramagola-Masire for providing testing space, Dr. Odile Bagie and the staff at the IDCC for assistance enrolling patients, Tumelo Molelekwana and the staff at the Telelopele Voluntary Testing and Counseling Centre (TVCTC) for assistance enrolling control subjects, Katherine Steele for data entry, Drs. Pablo Tebas, Dennis Kolson, and Ronald Collman for suggestions concerning the study design, and Liyi Chen for data analysis. We are grateful for the valuable suggestions of two anonymous reviewers.

Author Contributions

Conceived and designed the experiments: KL APS MM. Performed the experiments: KL KJ. Analyzed the data: SJR CC. Contributed reagents/materials/analysis tools: KL MM ES. Wrote the paper: KL KJ SJR CC ES APS. Creation of the BAVLT: KL MM ES. Supervision of patient enrollment: MM.
References

1. UNAIDS, NACA Botswana-2010 Country Progress Report, UNAIDS website. Available: http://www.unaids.org/en/CountryResponses/Countries/botswana. asp. Accessed 2011 Jan 30.
2. Scaravilli F (1993) Neuropathology of HIV infection. London: Springer-Verlag.
3. An SF, Groves M, Gray F, Scaravilli F (1999) Early entry and widespread cellular involvement of HIV-1 DNA in brains of HIV-1 positive asymptomatic individuals. Journal of Neuropathology and Experimental Neurology 58(11): 1156–1162. PMID 10566568.
4. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, et al. (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69: 1799–1809. DOI:10.1212/01.WNL.0000274131.81650.8b.
5. Osowiecki DM, Cohen RA, Morrow KM, Paul RH, Carpenter CC, et al. (2000) Neurocognitive and psychological contributions to quality of life in HIV-1 infected women. AIDS 14: 1327–1332. PMID 10930416.
6. Heaton RK, Marcotte TD, Rivera Mindt M, Sadek J, Moore D, et al. (2004) The impact of HIV-associated neurocognitive impairment on everyday functioning. J Int Neurpsychol Soc 10: 317–331. PMID 15147590.
7. Dawes S, Suarez P, Casey CY, Cherner M, Marcotte TD, et al. (2008) Variable patterns of neuropsychological performance in HIV-1 infection. Journal of Clinical and Experimental Neuropsychology 30(6): 613–636. PMID 18608069.
8. Heaton RK, Franklin D, Clifford D, Woods S, Rivera Mindt M (2009) HIV-associated neurocognitive impairment remains prevalent in the era of combination art: the Charter study. Paper presented at the 16th Conference on Retroviruses and Opportunistic Infections, Montreal. retroconference.org/2009/display.aspx?page=396.
9. Bhaskaran KM, Musini C, Antinori A, Walker SA, Dorracci M, the CASCADE Collaboration (2008) Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Annal of Neurology 63(2): 213–221. PMID 17894380.
10. Wright E, Brew A, Ayarawichans A, Robertson K, Samnikarapanya K, et al. (2008) Neurological disorders are prevalent in HIV positive outpatients in the Asia-Pacific region. Neurol 71(1): 50–56. PMID 18391505.
11. Sacktor N, Wong M, Nakasujja N, Skolasky RL, Selnes O, et al. (2005) The international HIV dementia scale: a rapid new screening test for HIV dementia. AIDS 19(13): 1367–1374.
12. Clifford DB, Minke MT, Mekonnen Y, Zhang J, Zenebe G, et al. (2007) Neurological evaluation of untreated human immunodeficiency virus infected adults in Ethiopia. Journal of Neurology 15(1): 67–72.
13. Wong M, Robertson K, Nakasujja N, Skolasky R, Musisi S, et al. (2007) Frequency of and risk factors for HIV dementia in sub-Saharan Africa. Neurol 68(5): 330–335.
14. Kamnognge GD, Kuate CT, Cyisique LA, Fonshon JY, Eta S, et al. (2010) HIV-associated neurocognitive disorders in sub-Saharan Africa: a pilot study in Cameroon. BMC Neurol 10: 60.
15. Nakasujja N, Wong M, Robertson K, McArthur J, Sacktor N (2004) HIV-associated neurological complications among HIV-seropositive individuals in Uganda. Neurology 62: A44.
16. Gupta JD, Satishchandra P, Kumarapillai G, Wilkie F, Waldrop-Valverde D, et al. (2007) Neuropsychological deficits in human immunodeficiency virus type 1 clade C-seropositive adults from South India. J of NeuroVirology 13(6): 195–202.
17. Heaton RK, Cyisique L, Hsu J, Chai C, Xin Y, the San Diego HIV NRCG (2008) Neurobehavioral effects of human immunodeficiency virus infection among former plasma donors in rural China. J of NeuroVirology 14: 536–549.
18. Joska JA, Westgarth-Taylor J, Myer L, Houre J, Thomas KG, Conbruck M, Paul RH, Stein DJ, Fisher AJ (2010) Characterization of HIV-associated neurocognitive disorders among individuals starting antiretroviral therapy in South Africa. AIDS Behav, 2010 Jul Epub ahead of print.
19. Cyisique LA, Brew J (2009) Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychology Review 19(2): 169–185.
20. Cyisique LA, Letendre SL, Ake C, Jin H, Franklin DR, Jr., the HIV Neurobehavioral Research Center Group (2010) Incidence and nature of cognitive decline over 1 year among HIV-infected former plasma donors in China. AIDS 24(7): 983–990.
21. Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, et al. (2004) Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 26: 307–319.
22. Cyisique LA, Maruff P, Brew BJ (2006) Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology 66: 1447–1450.
23. Robertson K, Liner J, Heaton R (2009) Neuropsychological assessment of HIV-infected populations in international settings. Neuropsych Rev 19: 232–249.
24. Maj M, Satz P, Janssen R, Ausdug M, Starace F, et al. (1994) WHO Neuropsychiatric AIDS study, cross-sectional phase II: neurobehavioral and neurological findings. Archives of General Psychiatry 51(1): 51–61.
25. Sacktor N, Nakasujja N, Skolasky R, Robertson K, Wong M, et al. (2006) Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa. Neurology 67(2): 311–314.
26. Liner H, Mathews C, Robertson KR (2007) Impact of human immunodeficiency virus (HIV) subtypes on HIV-associated neurological disease. J of NeuroVirology 13: 291–304.
27. Lawler K, Mospele M, Ratcliffe S, Selnes O, et al. (2010) Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study. J Int AIDS Soc 13(1): 15.
28. Wechsler D, Wechsler Adult Intelligence Scale—Third Edition. New York: The Psychological Corporation.
29. Woods SP, Scott JC, Sires DA, Grant I, Heaton RK, et al. (2003) Action (verb) fluency: Test-retest reliability, normative standards, and construct validity. Journal of the International Neuropsychological Society 11: 408–415.
30. Cyisique LA, Jin H, Franklin Jr. DR, Morgan EE, Shi C, the BRNC Group (2007) Neurobehavioral effects of HIV-1 infection in China and the United States: A pilot study. J of International Neuropsychological Society 13: 761–790.
31. Robertson KR, Nakasujja N, Wong M, Musisi S, Katabira E, et al. (2007) Pattern of neuropsychological performance among HIV positive patients in Uganda, BMC Neurology 7: 8.
32. Reitan RM, Wolfonton D (1985) The Halstead-Reitan neuropsychological test battery. Tucson, AZ: Neuropsychology Press.
33. Maj M, D’Elia L, Shatz P, et al. (1993) Evaluation of two new neuropsychological tools designed to minimize cultural bias in the assessment of HIV-1 seropositive persons: A WHO study, Archives of Clinical Neuropsychology 8: 125–135.
34. Lafayette Instrument Grooved Peg Board Test, Lafayette, IN, Lafayette Instruments website. Available: www.lafayetteinstrument.com/. Accessed 2011 Jan 30.
35. Spitzer R, Williams J, Kroenke D, Linzer M, deGryff IV, et al. (1994) Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD study. JAMA 272: 1749–1756.
36. American Psychiatric Association (1994) Diagnostic and statistical manual for mental disorders—fourth edition (DSM-IV).
37. Tommasello AC, Gills LM, Lawler JT, Bujak G (2006) Characteristics of homeless HIV-positive outreach respondents in urban US and their success in primary care treatment, AIDS Care 18(8): 911–917.
38. Lawler K, Mospele M, Selnes O, Ratcliffe S, Steele K, et al. (2011) Depression among HIV-positive individuals in Botswana: a behavioral surveillance. AIDS Behav 15(1): 204. Epublished ahead of print 2009, DOI 10.1007/s10461-009-9622-2.
39. Han J, Atkinson JH, Xin Y, Heaton RK, Chuan SJ, HNRC China collaboration group (2006) Depression and suicidality in HIV/AIDS in China. J of Affective Disorders 94: 269–273.
40. Botswana National HIV/AIDS Treatment Guidelines. 1. Department of HIV/ AIDS Prevention and Care, Botswana. 2008. AIDSSTAR-One website. Available: http://www.aidsstar-one.com/treatment-documents. Accessed 2011 Jan 30.
41. Levendremarquist BJ, Caparelli E, Best B, Clifford D, et al. (2008) Validation of the CNS penetration effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65(1): 63–70.
42. Tozzi V, Balestra P, Salvatori M, Vlassa C, Lazzu G, et al. (2009) Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J AIDS 52(1): 56–63.
43. Sacktor N, Nakasujja N, Cliford D (2007) HIV-associated cognitive impairment in sub-Saharan Africa—the potential effect of Clade diversity. Nat Clin Pract Neuro 3(3): 436–443.
44. Livingston J (2009) Suicide, risk, and investment in the heart of the African miracle. Cultural Anthropology 24(4): 652–680.